<header id=043610>
Published Date: 2022-04-05 12:42:05 EDT
Subject: PRO/ALL> New in IJID (04): April 2022
Archive Number: 20220405.8702421
</header>
<body id=043610>
NEW IN INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (04): APRIL 2022
********************************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org

Date: April 2022
Source: IJID [edited]
https://www.ijidonline.com/


Coronavirus (COVID-19) collection
---------------------------------
Reviews
-------
Systematic review and meta-analysis of olfactory and gustatory dysfunction in COVID-2019.
Liu N et al.
Int J Infect Dis. 2022; 117: 155-161
https://doi.org/10.1016/j.ijid.2022.02.004

Clinical
--------
Characteristics and outcomes of COVID-19 in reproductive-aged pregnant and non-pregnant women in Osaka, Japan.
Zha L et al.
Int J Infect Dis. 2022; 117: 195-200
https://doi.org/10.1016/j.ijid.2022.01.054

Exploring the trajectory recovery curve of the number of post-COVID symptoms: the LONG-COVID-EXP-CM Multicenter Study.
Fernández-de-las-Peñas C et al.
Int J Infect Dis. 2022; 117: 201-3
https://doi.org/10.1016/j.ijid.2022.02.010

Development and validation of CoV19-OM Intensive Care Unit Score: an early ICU identification for laboratory-confirmed SARS-CoV-2 patients from a retrospective cohort study in Oman.
Lacap Jr EM et al.
Int J Infect Dis. 2022; 117: 241-6
https://doi.org/10.1016/j.ijid.2021.04.069

Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries.
Morita Y et al.
Int J Infect Dis. 2022; 117: 302-11
https://doi.org/10.1016/j.ijid.2022.02.024

Diagnostics
-----------
The low yield of SARS-CoV-2 rapid antigen testing in screening asymptomatic hospital visitors in low-incidence settings.
Boddeti NL et al.
Int J Infect Dis. 2022; 117: 27-27
https://doi.org/10.1016/j.ijid.2022.01.046

A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): a consensus of Latin American experts.
Fay FF et al.
Int J Infect Dis. 2022; 117: 130-136
https://doi.org/10.1016/j.ijid.2021.05.011

Performance of anterior nares and tongue swabs for nucleic acid, nucleocapsid and spike antigen testing for detecting SARS-CoV-2 against nasopharyngeal PCR and viral culture.
Montaño MA et al.
Int J Infect Dis. 2022; 117: 287-94
https://doi.org/10.1016/j.ijid.2022.02.009

Treatment
---------
Treatment with tocilizumab in adult patients with moderate to critical COVID‐19 pneumonia: a single‐center retrospective study.
Radulescu A et al.
Int J Infect Dis. 2022; 117: 1-7
https://doi.org/10.1016/j.ijid.2022.01.048

Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.
San-Juan R et al.
Int J Infect Dis. 2022; 117: 56-64
https://doi.org/10.1016/j.ijid.2022.01.040

Impact of antibody cocktail therapy combined with casirivimab and imdevimab on clinical outcome for COVID-19 patients in a real-life setting: a single institute analysis.
Kakinoki Y et al.
Int J Infect Dis. 2022; 117: 189-194
https://doi.org/10.1016/j.ijid.2022.01.067

Immunology and pathophysiology
------------------------------
The presence of anti-SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization.
Lippi G et al.
Int J Infect Dis. 2022; 117: 24-24
https://doi.org/10.1016/j.ijid.2022.01.057

Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in _Candida_ spp colonized patients.
Viciani E et al.
Int J Infect Dis. 2022; 117: 233-40
https://doi.org/10.1016/j.ijid.2022.02.011

Reduced ADAMTS13 activity in correlation with pathophysiology, severity, and outcome of COVID-19: a retrospective observational study.
Hafez W et al.
Int J Infect Dis. 2022; 117: 334-44
https://doi.org/10.1016/j.ijid.2022.02.019.

Evidence of SARS-CoV-2 symptomatic reinfection in four health care professionals from the same hospital despite the presence of antibodies.
Gargouri S et al.
Int J Infect Dis. 2022; 117: 146-54
https://doi.org/10.1016/j.ijid.2022.01.006

Vaccines
--------
Evaluation of immunogenicity by pseudovirus neutralization assays for coronavirus disease 2019 (COVID-19) variants after primary and booster immunization.
Xie H et al.
Int J Infect Dis. 2022; 117: 97-102
https://doi.org/10.1016/j.ijid.2022.01.068

Serological reactivity of inactivated SARS-CoV-2 vaccine based on an S-RBD neutralizing antibody assay.
Zhang H et al.
Int J Infect Dis. 2022; 117: 169-173
https://doi.org/10.1016/j.ijid.2022.01.064

Public health
-------------
Contact tracing period and epidemiological characteristics of an outbreak by SARS-CoV-2 delta variant in Guangzhou.
Ma X et al.
Int J Infect Dis. 2022; 117: 18-23
https://doi.org/10.1016/j.ijid.2022.01.034

Fending off delta -- hospital measures to reduce nosocomial transmission of COVID-19.
Lim RHF et al.
Int J Infect Dis. 2022; 117: 139-145
https://doi.org/10.1016/j.ijid.2022.01.069

Inferring the effective start dates of non-pharmaceutical interventions during COVID-19 outbreaks.
Kohanovski I et al.
Int J Infect Dis. 2022; 117: 361-8
https://doi.org/10.1016/j.ijid.2021.12.364

Epidemiology
------------
SARS-CoV-2 transmission in northwest Syria: modelling pandemic responses and vaccination during political conflict.
Marzouk M et al.
Int J Infect Dis. 2022; 117: 103-115
https://doi.org/10.1016/j.ijid.2022.01.062

Epidemiological and clinical features of SARS-CoV-2 cluster infection in Anhui Province, Eastern China.
Wu J et al.
Int J Infect Dis. 2022; 117: 372-7
https://doi.org/10.1016/j.ijid.2021.04.064

Case reports
------------
Exclude differentials before diagnosing SARS-CoV-2 acute, hemorrhaghic, necrotising encephalitis.
Finsterer J et al.
Int J Infect Dis. 2022; 117: 220-221
https://doi.org/10.1016/j.ijid.2022.02.018

Immunological changes after COVID-19 vaccination in an HIV-positive patient.
Gong C et al.
Int J Infect Dis. 2022; 117: 230-2
https://doi.org/10.1016/j.ijid.2021.08.039

Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis.
Wibowo A et al.
Int J Infect Dis. 2022; 117: 267-73
https://doi.org/10.1016/j.ijid.2021.06.051

SARS-CoV-2 attacks the weakest point -- COVID-19 course in a pediatric patient with Friedreich's ataxia.
Faltin K et al.
Int J Infect Dis. 2022; 117: 284-6
https://doi.org/10.1016/j.ijid.2021.06.051

Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA-1273 vaccine: a case report.
Kamura Y et al.
Int J Infect Dis. 2022; 117: 322-5
https://doi.org/10.1016/j.ijid.2022.02.021

Correspondence
--------------
Reply to letter to the editor by Lippi and Plebani: "The presence of anti-SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization" (THEIJID-D-22-00085).
Gargouri S et al.
Int J Infect Dis. 2022; 117: 137-8
https://doi.org/10.1016/j.ijid.2022.01.059

Correspondence on "The low yield of SARS-CoV-2 rapid antigen testing in screening asymptomatic hospital visitors in low-incidence settings".
Wee LE et al.
Int J Infect Dis. 2022; 117: 187-8
https://doi.org/10.1016/j.ijid.2022.01.049

Non-COVID-19 collection
------------------------
Perspectives
------------
Interventional research to tackle antimicrobial resistance in Low Middle Income Countries in the era of the COVID-19 pandemic: lessons in resilience from an international consortium.
Birgand G et al.
Int J Infect Dis. 2022; 117: 174-8
https://doi.org/10.1016/j.ijid.2022.02.013

The Abbott pandemic defense coalition: a unique multi-sector approach adds to global pandemic preparedness efforts.
Averhoff F et al.
Int J Infect Dis. 2022; 117: 356-60
https://doi.org/10.1016/j.ijid.2022.02.001

Reviews
-------
What is the true burden of diphtheria, tetanus, pertussis, and poliovirus in children aged 3-18 in Asia? A systematic literature review.
Nicholson L et al.
Int J Infect Dis. 2022; 117: 116-29
https://doi.org/10.1016/j.ijid.2022.01.045

Clinical, microbiological, and imaging characteristics of infective endocarditis in Latin America: a systematic review.
Urina-Jassir M et al.
Int J Infect Dis. 2022; 117: 312-21
https://doi.org/10.1016/j.ijid.2022.02.022

Bacterial infections
--------------------
Risk factors for polymyxin B-associated acute kidney injury.
Chang K et al.
Int J Infect Dis. 2022; 117: 37-44
https://doi.org/10.1016/j.ijid.2022.01.055

Genome-wide networks reveal emergence of epidemic strains of _Salmonella_ Enteritidis.
Svahn AJ et al.
Int J Infect Dis. 2022; 117: 65-73
https://doi.org/10.1016/j.ijid.2022.01.056

A citywide, clonal outbreak of _Pseudomonas aeruginosa_.
Opperman CJ et al.
Int J Infect Dis. 2022; 117: 74-86
https://doi.org/10.1016/j.ijid.2022.01.039

Automated susceptibility testing with Vitek 2 compared to MicroScan reduces vancomycin alternative therapy for methicillin-resistant _Staphylococcus aureus_ bacteremia.
Rose DT et al.
Int J Infect Dis. 2022; 117: 179-86
https://doi.org/10.1016/j.ijid.2022.02.002

Tuberculosis
------------
Development of population pharmacokinetics model of isoniazid in Indonesian tuberculosis patients.
Soedarsono S et al.
Int J Infect Dis. 2022; 117: 8-14
<https://doi.org/10.1016/j.ijid.2022.01.003

Arterial partial pressure of oxygen and procalcitonin levels correlate with pulmonary artery systolic pressure in patients with active pulmonary tuberculosis.
Li WT et al.
Int J Infect Dis. 2022; 117: 87-92
https://doi.org/10.1016/j.ijid.2022.01.060

Molecular epidemiology and genetic diversity of _Mycobacterium tuberculosis_ complex in Mali: what is new?
Kone B et al.
Int J Infect Dis. 2022; 117: 204-11
https://doi.org/10.1016/j.ijid.2022.01.061

Effect of implementation of a 12 dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: interrupted time series design.
Alvarez GG et al.
Int J Infect Dis. 2022; 117: 222-9
https://doi.org/10.1016/j.ijid.2022.01.063

Pulmonary tuberculosis and management of contact patients in a department of nephrology and kidney transplantation.
Burguet L et al.
Int J Infect Dis. 2022; 117: 251-7
https://doi.org/10.1016/j.ijid.2021.05.045

First outbreak of multidrug-resistant tuberculosis (MDR-TB) in Denmark involving six Danish-born cases.
Suppli CH et al.
Int J Infect Dis. 2022; 117: 258-63
https://doi.org/10.1016/j.ijid.2022.02.017

Viral infections
----------------
Epidemiological patterns of hepatitis A infection in the pre-vaccination Era: a population based survey in Tunisia in 2015.
Saffar F et al.
Int J Infect Dis. 2022; 117: 162-8
https://doi.org/10.1016/j.ijid.2022.01.004

Mannose-binding lectin levels and MBL2 gene polymorphisms are associated to dengue infection in Brazilian children at the early ages.
Sena MA et al.
Int J Infect Dis. 2022; 117: 212-9
https://doi.org/10.1016/j.ijid.2022.02.012

Molecular characterization of the viral structural genes of human rhinovirus A11 from children hospitalized with lower respiratory tract infection in Kunming.
Zhang Z et al.
Int J Infect Dis. 2022; 117: 274-83
https://doi.org/10.1016/j.ijid.2022.01.066

COVID-19 and Lassa fever in Nigeria: a deadly alliance?
Musa SS et al.
Int J Infect Dis. 2022; 117: 45-47
https://doi.org/10.1016/j.ijid.2022.01.058

A challenging response to a Lassa fever outbreak in a non-endemic area of Sierra Leone in 2019, with export of cases to the Netherlands.
Njuguna C et al.
Int J Infect Dis. 2022; 117: 295-301
https://doi.org/10.1016/j.ijid.2022.02.020

Serotype identification of human adenoviruses associated with influenza-like illnesses in the Philippines from 2006 to 2012 by microneutralization and molecular techniques.
Calzado-Dacasin C et al.
Int J Infect Dis. 2022; 117: 326-33
https://doi.org/10.1016/j.ijid.2022.02.008

HIV
---
Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study.
Xiao J et al.
Int J Infect Dis. 2022; 117: 48-55
https://doi.org/10.1016/j.ijid.2022.01.051

Parasitic infections
--------------------
Migration characteristics as a prognostic factor in cerebral sparganosis.
Feng L et al.
Int J Infect Dis. 2022; 117: 28-36
https://doi.org/10.1016/j.ijid.2022.01.005

Colombian Ocular Infectious Epidemiology Study (COIES): Ocular toxoplasmosis incidence and sociodemographic characterization, 2015-2019.
Cifuentes-González C et al.
Int J Infect Dis. 2022; 117: 349-55
https://doi.org/10.1016/j.ijid.2022.02.028

Potential use of antibodies to provide an earlier indication of potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post-mass drug administration surveillance, American Samoa.
Cadavid Restrepo AM et al.
Int J Infect Dis. 2022; 117: 378-86
https://doi.org/10.1016/j.ijid.2022.02.006

Disseminated hepatic and peritoneal hydatidosis mimicking acute abdomen.
Hajri M et al.
Int J Infect Dis. 2022; 117: 25-6
https://doi.org/10.1016/j.ijid.2022.01.052

Hospital infection control
--------------------------
Virtual infection prevention and control in low- and middle-income countries.
Jones T et al.
Int J Infect Dis. 2022; 117: 93-96
https://doi.org/10.1016/j.ijid.2022.01.065

Case reports
------------
Mediterranean spotted fever and peripheral facial nerve palsy: a rare neurological complication.
Bouchaib H et al.
Int J Infect Dis. 2022; 117: 15-17
https://doi.org/10.1016/j.ijid.2022.01.050

Misdiagnosis of cerebral sparganosis coexisting with HIV/AIDS: a case report.
Liu C et al.
Int J Infect Dis. 2022; 117: 264-6
https://doi.org/10.1016/j.ijid.2022.02.016

Status epilepticus with focal neurological deficits: a rare presentation of neurosyphilis.
Qi Y et al.
Int J Infect Dis. 2022; 117: 345-8
https://doi.org/10.1016/j.ijid.2022.02.029

Persistent _Clostridium difficile_ colitis mimicking a fatal case of strongyloides hyperinfection syndrome.
Grossman J et al.
Int J Infect Dis. 2022; 117: 369-71
https://doi.org/10.1016/j.ijid.2022.02.023

Correspondence
--------------
Sporotrichoid distributed tuberculous panniculitis as a late complication of intravesical bacillus Calmette-Guérin (BCG) immunotherapy.
Nielens N et al.
Int J Infect Dis. 2022; 117: 247-50
https://doi.org/10.1016/j.ijid.2021.05.003

--
communicated by:
ProMED
See Also
New in IJID (03): March 2022 20220304.8701795
New in IJID (02): February 2022 20220206.8701298
New in IJID (01): December 2021 20220109.8700756
2021
---
New in IJID (11): November 2021 20211205.8700079
New in IJID (10): October 2021 20211107.8699506
New in IJID (09): September 2021 20211007.8698901
New in IJID (08): August 2021 20210907.8651803
New in IJID (07): July 2021 20210812.8580841
New in IJID (06): June 2021 20210722.8536790
New in IJID (05): May 2021 20210516.8364910
New in IJID (04): April 2021 20210421.8319851
New in IJID (03): March 2021 20210316.8250191
.................................................ep/mj/sh
</body>
